Summarizing, PRL/PRLR signalling may elicit very different outcomes depending on the biological sex of the patient and glioma grade, factors that need to be taken into consideration before translating therapies using PRLR antagonists to the neuro-oncology clinic. This evidence concerns the gene PRL and glioma.